ALTAO
Aton operates as a bioscience company in France. It engages in drug development, preclinical and clinical services, production of monoclonal antibodies, laboratory equipment production, and designing and manufacturing of medical devices, as well as provision of human tissues. The company also offers medical devices for surgeons, powered by Stemcis. The company was founded in 1998 and is headquart… Read more
ALTAO (ALTAO) - Net Assets
Latest net assets as of June 2025: €415.00K EUR
Based on the latest financial reports, ALTAO (ALTAO) has net assets worth €415.00K EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€5.62 Million) and total liabilities (€5.21 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €415.00K |
| % of Total Assets | 7.38% |
| Annual Growth Rate | -7.76% |
| 5-Year Change | -83.87% |
| 10-Year Change | -95.05% |
| Growth Volatility | 146.29 |
ALTAO - Net Assets Trend (2009–2024)
This chart illustrates how ALTAO's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ALTAO (2009–2024)
The table below shows the annual net assets of ALTAO from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €791.00K | +116.88% |
| 2023-12-31 | €-4.69 Million | -145.79% |
| 2022-12-31 | €10.23 Million | +8.50% |
| 2021-12-31 | €9.43 Million | +92.36% |
| 2020-12-31 | €4.90 Million | -6.25% |
| 2019-12-31 | €5.23 Million | +308.00% |
| 2018-12-31 | €1.28 Million | -86.01% |
| 2017-12-31 | €9.16 Million | -15.84% |
| 2016-12-31 | €10.88 Million | -31.88% |
| 2015-12-31 | €15.98 Million | +45.16% |
| 2014-12-31 | €11.01 Million | +349.78% |
| 2013-12-31 | €2.45 Million | +76.93% |
| 2012-12-31 | €1.38 Million | +251.15% |
| 2011-12-31 | €-915.00K | -189.56% |
| 2010-12-31 | €-316.00K | -111.88% |
| 2009-12-31 | €2.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ALTAO's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1500700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €8.00 Million | 1011.50% |
| Other Components | €11.99 Million | 1516.18% |
| Total Equity | €791.00K | 100.00% |
ALTAO Competitors by Market Cap
The table below lists competitors of ALTAO ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NRB Industrial Bearings Limited
NSE:NIBL
|
$1.91 Million |
|
Wawel S.A.
F:0K6
|
$1.91 Million |
|
Drago entertainment S.A.
WAR:DGE
|
$1.91 Million |
|
Stern Groep N.V.
AS:PBH
|
$1.91 Million |
|
OZZ Resources Ltd
AU:OZZ
|
$1.91 Million |
|
Nuinsco Resources Limited
PINK:NWIFF
|
$1.91 Million |
|
SEATech Ventures Corp
PINK:SEAV
|
$1.91 Million |
|
Scisparc Ltd
NASDAQ:SPRC
|
$1.91 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ALTAO's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -4,685,879 to 791,000, a change of 5,476,879.
- Net loss of 1,071,000 reduced equity.
- Other factors increased equity by 6,547,879.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-1.07 Million | -135.4% |
| Other Changes | €6.55 Million | +827.8% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares ALTAO's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.87x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.03x to 5.87x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | €0.22 | €0.01 | x |
| 2010-12-31 | €-0.02 | €0.01 | x |
| 2011-12-31 | €-0.06 | €0.01 | x |
| 2012-12-31 | €0.07 | €0.01 | x |
| 2013-12-31 | €0.10 | €0.01 | x |
| 2014-12-31 | €0.41 | €0.01 | x |
| 2015-12-31 | €0.45 | €0.01 | x |
| 2016-12-31 | €0.30 | €0.01 | x |
| 2017-12-31 | €0.23 | €0.01 | x |
| 2018-12-31 | €0.03 | €0.01 | x |
| 2019-12-31 | €0.02 | €0.01 | x |
| 2020-12-31 | €0.02 | €0.01 | x |
| 2021-12-31 | €0.04 | €0.01 | x |
| 2022-12-31 | €0.04 | €0.01 | x |
| 2023-12-31 | €-0.01 | €0.01 | x |
| 2024-12-31 | €0.00 | €0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ALTAO utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -135.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -174.43%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 8.16x
- Recent ROE (-135.40%) is below the historical average (-84.55%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -157.80% | -100.65% | 0.50x | 3.14x | €-4.46 Million |
| 2010 | 0.00% | -122.03% | 0.54x | 0.00x | €-4.53 Million |
| 2011 | 0.00% | -101.64% | 0.39x | 0.00x | €-2.20 Million |
| 2012 | -181.78% | -53.62% | 0.65x | 5.24x | €-2.59 Million |
| 2013 | -74.16% | -31.80% | 0.71x | 3.28x | €-2.03 Million |
| 2014 | -26.62% | -52.62% | 0.33x | 1.54x | €-4.02 Million |
| 2015 | -27.51% | -94.39% | 0.22x | 1.34x | €-5.97 Million |
| 2016 | -48.65% | -145.78% | 0.22x | 1.50x | €-6.34 Million |
| 2017 | -86.88% | -423.24% | 0.13x | 1.53x | €-8.87 Million |
| 2018 | -587.33% | -9811.40% | 0.02x | 3.12x | €-7.66 Million |
| 2019 | -17.65% | -392.92% | 0.04x | 1.13x | €-1.45 Million |
| 2020 | -6.71% | -218.49% | 0.02x | 1.31x | €-819.41K |
| 2021 | 3.15% | 201.70% | 0.01x | 1.39x | €-646.39K |
| 2022 | -5.51% | -36126.28% | 0.00x | 1.49x | €-1.59 Million |
| 2023 | 0.00% | -4910.49% | 0.37x | 0.00x | €-18.38 Million |
| 2024 | -135.40% | -174.43% | 0.10x | 8.16x | €-1.15 Million |
Industry Comparison
This section compares ALTAO's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $11,397,324
- Average return on equity (ROE) among peers: -51.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ALTAO (ALTAO) | €415.00K | -157.80% | 12.55x | $1.91 Million |
| Abionyx Pharma SA (ABNX) | $8.89 Million | -56.01% | 1.06x | $72.33 Million |
| Abivax SA (ABVX) | $56.72 Million | -25.23% | 0.07x | $3.97 Billion |
| Adocia (ADOC) | $-6.91 Million | 0.00% | 0.00x | $84.57 Million |
| Aelis Farma SA (AELIS) | $898.00K | 63.92% | 30.53x | $5.01 Million |
| Acticor Biotech SAS (ALACT) | $-4.04 Million | 0.00% | 0.00x | $2.13 Million |
| NicOx S.A. (ALCOX) | $21.41 Million | -97.51% | 1.47x | $28.49 Million |
| Advicenne (ALDVI) | $-1.67 Million | 0.00% | 0.00x | $15.84 Million |
| ALGAE (ALGAE) | $32.76 Million | -39.31% | 0.56x | $29.13 Million |
| Genoway (ALGEN) | $5.23 Million | 9.60% | 1.10x | $23.45K |
| Integragen (ALINT) | $691.87K | -367.93% | 7.36x | $424.10K |